CymaBay’s stock surges as Gilead reaches $4.3 billion deal for liver-drug developer

CymaBay Therapeutics shares jumped 24% early Monday after Gilead Sciences reached a $4.3 billion deal to acquire the liver-drug developer.

Source: MarketWatch

Continue reading...